MedImmune refrigerated FluMist clears FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MedImmune is planning its own February thaw as it gears up to stop producing the frozen formulation of its intranasal influenza vaccine FluMist in favor of the newly-approved refrigerator-stable formulation when manufacturing begins next month, the company says. MedImmune announced FDA approval of the new FluMist formulation, also known as CAIV-T (cold adapted influenza vaccine, trivalent), for "healthy children and adults 5 years to 49 years of age" on Jan. 8. An indication for use in children ages 1 to 5 years has an estimated late-May user fee goal. MedImmune expects to manufacture 7 to 10 million doses of the new formulation, which is easier to distribute and store, for the 2007/2008 flu season - two to three times the 3 million doses of frozen FluMist manufactured for the 2006/2007 season. The fridge formulation will also be priced at a slight discount to the older version. FDA issued a "complete response" letter for refrigerated FluMist in July (1Pharmaceutical Approvals Monthly August 2006, p. 32); MedImmune responded Aug. 11, 2006 with additional information on bridging studies for both versions...
You may also be interested in...
Fridge-stable FluMist gets "complete response"
MedImmune says it continues to expect its refrigerator-stable formulation of FluMist (intranasal influenza vaccine live) will reach the market in time for the 2007-2008 flu season after receiving a "complete response" letter July 18. FDA is requesting clarification and additional information on the new formulation, which the company submitted July 28. MedImmune is seeking approval to switch formulations from frozen FluMist, indicated in healthy individuals 5 to 49 years of age, to the refrigerator-stable cold adapted influenza vaccine, trivalent (CAIV-T). MedImmune announced July 31 that it has submitted a FluMist sBLA to expand the treatment population down to pediatrics in the 12 to 59-month age range...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.